Diapoint Virtual Diabetes Series
In April, we launched the new Diapoint Virtual Diabetes Series. In these interviews we will speak with a variety of experts on a range of topics, and bring you the highlights on our website.
We loved having Dr Sarper Tanli, MD, PhD, as our guest on May 6, 2020.
These interviews are conducted on live Zoom conference calls. All are welcome. To be notified of our upcoming Diapoint Virtual Diabetes Series, join our mailing list. Also, follow us on Facebook, Instagram and Twitter to see our invites there.
Come and join us for our next instalment. We bring you these experts completely free of charge.
Dr Sarper Tanli, MD, PhD, MHA
Dr. Tanli is an experienced senior healthcare executive with years of experience in the GCC region. He has worked for years in models of healthcare that were once considered “alternative” before COVID19 – including digital health and home healthcare.
He holds an MD in Medicine, a Masters in Healthcare Administration from Istanbul University and a Ph.D. degree in Healthcare Management from Marmara University.
He is currently the Group Chief Executive Officer of Manzil Health Care Services. He has extensive experience in healthcare planning, development, operations and informatics on an international scale. He is also an alumni of the GCC Board of Directors Institute.
In addition to his vast medical experience, Dr. Tanli also has a son who has Type 1 Diabetes.
In this interview, we discuss:
- What exactly is Telemedicine?
- How does Telemedicine support treatment in diabetes and other conditions?
- What do we need to know, and how should we prepare when our doctor suggests a Telemedicine consultation?
Listen to Dr Sarper Tanli Speak About Telemedicine
More From Our Diabetes Experts
To find our other interviews in the Diapoint Virtual Diabetes Series, plus more interviews with diabetes experts, check out our Ask The Diabetes Expert blog posts.
Join the DiapointME mailing list
Sign up below to become part of the DiapointME online community.
By joining the DiapointME mailing list, you are giving us permission to send you emails. You are also agreeing to our Privacy Policy.
